Objectives: The aims of the study were (1) to document the demography and clinical profile of patients with leprosy at a tertiary referral center from 2009 to 2018. (2) To compare the disease manifestation in children aged 12 years/below and the same in patients above 12 years. Materials and Methods: Case records of all patients diagnosed to have leprosy as per the World Health Organization cardinal criteria at our tertiary referral center from 2009 to 2018 were included in this study. The findings recorded in those aged 12 years/below were compared with those above 12 years using Pearson’s Chi- square test. Results: A total of 705 patients who attended our institution during the 10 year period were diagnosed to have leprosy. Six hundred and sixty-four (94.2%) were above 12 years of age and 41 patients (5.8%) were aged 12 years or below. Lepromatous spectrum cases, pure neuritic cases, Grade 2 disability, and lepra reactions were not documented in any of the patients aged 12 years or below which were contrary to the observations in those above 12 years. The differences were found to be statistically significant. Limitations: Retrospective design and small number of childhood cases were the main limitations of the study. Conclusion: Clinical presentation of leprosy in children differs from that in adults. Detection of disease in childhood offers an opportunity to cure the disease with less risk of developing some of the important disease and therapy-related complications.

<p class="abstract">Cutaneous manifestations observed in COVID-19 include maculopapular rash, urticaria, pseudo chilblain, vesicles, livedo reticularis, petechiae, erythema multiforme-like, symmetric drug related intertriginous and flexural exanthem (SDRIFE)-like and pityriasis rosea-like lesions. Maculopapular rash involving the trunk and sparing palms and soles is the most common cutaneous manifestation reported in COVID-19 patients. We report cutaneous manifestations in six COVID-19 patients from the corona isolation ward and intensive care unit of a tertiary care center for COVID-19 management in Kerala, South India. The skin lesions observed were urticaria (two patients), atypical maculopapular rash with urticarial and erythema multiforme-like lesions, eruptive pseudoangiomatosis, exaggerated insect bite reaction and acute localized exanthematous pustulosis (ALEP)-like lesions. To the best of our knowledge atypical maculopapular rash with urticarial and erythema multiforme-like lesions, eruptive pseudoangiomatosis and acute localized exanthematous pustulosis-like lesions are not reported in COVID-19.</p>

No abstract